Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 2: Second-line drugs;Drogas antituberculose: Interações medicamentosas, efeitos adversos e utilização em situações especiais. Parte 2: Fármacos de segunda linha

Jornal Brasileiro de Pneumologia

Volumn 36, Issue 5, 2010, Pages 641-656

  Arbex, Marcos Abdo ^a,b   Varella, Marília de Castro Lima ^c   de Siqueira, Hélio Ribeiro ^d   de Mello, Fernando Augusto Fiúza ^e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Nestor Goulart Reis   (Brazil)

^c UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e Secretary of Health of Sa o Paulo State   (Brazil)

Author keywords

Antibiotics; Antitubercular; Drug interactions; Drug toxicity; Multidrug resistant; Pharmacologic actions; Tuberculosis

Indexed keywords

EID: 78649414416     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/s1806-37132010000500017     Document Type: Review

References (60)

1. Ministe ́rio da Sau ́de. Secretária de Vigilância em Sau ́de. Departamento de Vigilância Epidemiológica. Programa Nacional de Controle da Tuberculose. Nota técnica sobre as mudanças no tratamento da tuberculose no Brasil para adultos e adolescentes - versão 2. Brasília: Ministério da Saúde; 2009.
2. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. Geneva: World Health Organization, Stop TB Department; 2008.
3. Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pde T, et al. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol. 2009;35(10):1018-1048.
4. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769-782.
5. Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-564.
6. Rieder HL. Intervenciones para el control y la eliminación de la tuberculosis. Paris; Unión internacional contra la tuberculosis y enfermedades respiratorias. 2007; p. 32-35.
7. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am. 2009;23(4):1053-1075, x.
8. Coll P. Active drugs against Mycobacterium tuberculosis [Article in Spanish]. Enferm Infecc Microbiol Clin. 2009;27(8):474-480.
9. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79(1):3-29.
10. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-662.
11. World Health Organization. The Treatment of Tuberculosis Guidelines. Geneva: World Health Organization; 2010.
12. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538-1544.
13. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008;249(2-3):91-96.
14. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549-1555.
15. Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S, et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother. 2003;47(3):1010-1016.
16. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6(7):622-627.
17. Pai MP, Momary KM, Rodvold KA. Antibiotic drug interactions. Med Clin North Am. 2006;90(6):1223-1255.
18. Gilbert DN, Leggett JE. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone/Elsevier; 2009. p. 359-84.
19. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis. 1985;131(3):352-356.
20. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3(7):432-442.
21. Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother. 2004;54(3):593-602.
22. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849-862.
23. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003;124(4):1476-1481.
24. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359(6):563-574.
25. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169(10):1103-1109.
26. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb). 2008;88 Suppl 1:S65-S74.
27. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev. 2008;(1):CD004795.
28. Yoon YS, Lee HJ, Yoon HI, Yoo CG, Kim YW, Han SK, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis. 2005;9(11):1215-1219.
29. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009;180(4):365-370.
30. Chang KC, Leung CC, Yew WW, Lau TY, Leung WM, Tam CM, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur Respir J. 2010;35(3):606-613.
31. Suh B, Lorber B. Quinolones. Med Clin North Am. 1995;79(4):869-894.
32. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):119-121.
33. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):127-131.
34. O'Donnell JA, Gelone SP. Fluoroquinolones. Infect Dis Clin North Am. 2000;14(2):489-513, xi.
35. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62(1):13-59.
36. Bolon MK. The newer fluoroquinolones. Infect Dis Clin North Am. 2009;23(4):1027-1051, x.
37. Giamarellou H, Kolokythas E, Petrikkos G, Gazis J, Aravantinos D, Sfikakis P. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med. 1989;87(5A):49S-51S.
38. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002;25(2):111-133.
39. Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Comissão de Controle de Infecção Hospitalar. Normas para o diagnóstico, tratamento, isolamento e prevenção da tuberculose. São Paulo: Hospital das Clínicas/FMUSP; 2009.
40. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(11):1320-1330.
41. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):100-101.
42. Ministério da Saúde. Secretaria de Vigilância em Saúde. Centro de Referência Prof. Hélio Fraga. Tuberculose Multirresistente: Guia de Vigilância Epidemiológica. Rio de Janeiro: Centro de Referência Professor Hélio Fraga/ SVS/Ministério da Saúde e Projeto MSH; 2007.
43. Seaworth BJ. Multidrug-resistant tuberculosis. Infect Dis Clin North Am. 2002;16(1):73-105.
44. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789.
45. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. Chest. 1999;116(4):984-990.
46. Caminero Luna JA. Guía de la Tuberculosis para Médicos Especialistas. Paris: Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias; 2003.
47. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003;47(12):3799-3805.
48. Migliori GB, D'Arcy Richardson M, Sotgiu G, Lange C. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med. 2009;30(4):637-665, vii.
49. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):106-108.
50. Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax. 2001;56(6):494-499.
51. Shin S, Guerra D, Rich M, Seung KJ, Mukherjee J, Joseph K, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis. 2003;36(8):996-1003.
52. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88(2):89-91.
53. Wallace RC, Griffith DE. Antimycobacterial agents. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone/ Elsevier; 2009. p. 533-548.
54. Para-aminosalicylic acid. Tuberculosis (Edinb). 2008;88(2):137-138.
55. Petri WA. Quimioterapia da tuberculose, complexo mycobacterium avium e hanseníase. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman - As Bases Farmacológicas da Terapêutica. Rio de Janeiro: McGraw-Hill; 2006. p.1083-1101.
56. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169-2183.
57. Silva Jr JB. Tuberculose: Guia de vigilância epidemiológica. J Bras Pneumol. 2004;30(Suppl 1):S57-S86.
58. Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro de Referência Professor Hélio Fraga. Sociedade Brasileira de Pneumologia e Tisiologia. Controle da tuberculose: uma proposta de integração ensino-serviço. Rio de Janeiro: FUNASA/CRPHF/SBPT; 2002.
59. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th ed. Geneva: World Health Organization; 2009.
60. Morrone N, Marques JF, Fazolo N, Soares LC, Macedo L. Reações adversas das drogas tuberculostáticas. J Pneumol. 1993;19:52-59.